Trends in 'poor responder' research: Lessons learned from RCTs in assisted conception

Human Reproduction Update

Volumn 22, Issue 3, 2016, Pages 306-319

  Papathanasiou, Athanasios ^a   Searle, Belinda J ^a   King, Nicole M A ^b   Bhattacharya, Siladitya ^b  

^a Bourn Hall Clinic   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Blinding; IVF; Live birth; Low responder; Low response; Methodology; Ovarian stimulation; Poor responder; RCT; Review

Indexed keywords

ACETYLSALICYLIC ACID; CLOMIFENE CITRATE; ESTROGEN; FOLLITROPIN; LETROZOLE; METFORMIN; PRASTERONE;

ARTICLE; CELL COUNT; CONCEPTION; DOWN REGULATION; DRUG MICRODOSE; EMBRYO TRANSFER; FERTILIZATION IN VITRO; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HUMAN; INTENTION TO TREAT ANALYSIS; LIVE BIRTH; LUTEAL PHASE; OOCYTE; PREGNANCY OUTCOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPONTANEOUS ABORTION; TREND STUDY; FEMALE; IN VITRO FERTILIZATION; METHODOLOGY; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREGNANCY; PROCEDURES; STANDARDS; TREATMENT FAILURE;

DOWN-REGULATION; FEMALE; FERTILIZATION IN VITRO; HUMANS; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT FAILURE;

EID: 84965054938     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmw001     Document Type: Article

References (97)

1. Aghahosseini M, Aleyassin A, Khodaverdi S, Esfahani F, Mohammadbeigi R, Movahedi S, Kord Valeshabad A, Mahdavi A, Fallahi P, Shabani P et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. J Assist Reprod Genet 2011;9:785-790.
2. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 2001;5:868-870.
3. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011;5:CD001750.
4. Artini PG, Simi G, Ruggiero M, Pinelli S, Di Berardino OM, Papini F, Papini S, Monteleone P, Cela V. DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecol Endocrinol 2012;9: 669-673.
5. Baerwald A, Anderson P, Yuzpe A, Case A, Fluker M. Synchronization of ovarian stimulation with follicle wave emergence in patients undergoing in vitro fertilization with a prior suboptimal response: a randomized, controlled trial. Fertil Steril 2012;4:881-882.
6. Bahceci M, Ulug U, Ciray HN, Akman MA, Erden HF. Efficiency of changing the embryo transfer time from day 3 to day 2 among women with poor ovarian response: a prospective randomized trial. Fertil Steril 2006;1:81-85.
7. Braakhekke M, Kamphuis EI, Dancet EA, Mol F, van der Veen F, Mol BW. Ongoing pregnancy qualifies best as the primary outcome measure of choice in trials in reproductive medicine: an opinion paper. Fertil Steril 2014;5:1203-1204.
8. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009;5:465-493.
9. Busnelli A, Papaleo E, Del Prato D, La Vecchia I, Iachini E, Paffoni A, Candiani M, Somigliana E. A retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria. Hum Reprod 2015;2:315-322.
10. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009;9683:86-89.
11. Chatillon-Boissier K, Genod A, Denis-Belicard E, Felloni B, Chene G, Seffert P, Chauleur C. Prospective randomised study of long versus short agonist protocol with poor responder patients during in vitro fertilization. Gynecol Obstet Fertil 2012;11:652-657.
12. Chetkowski RJ. Consumer-friendly reporting of in vitro fertilization outcomes. Fertil Steril 2014;1:e7.
13. Cheung L, Lam P, Lok IH, Chiu TT, Yeung S, Tjer C, Haines CJ. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod 2005;3:616-621.
14. Davar R, Rahsepar M, Rahmani E.Acomparative study of luteal estradiol pre-treatment inGnRHantagonist protocols and inmicro dose flare protocols for poor-responding patients. Arch Gynecol Obstet 2013;1:149-153.
15. Dechartres A, Charles P, Hopewell S, Ravaud P, Altman DG. Reviews assessing the quality or the reporting of randomized controlled trials are increasing over time but raised questions about how quality is assessed. J Clin Epidemiol 2011; 64:136-144.
16. Demirol A, Gurgan T. Comparison of microdose flare-up and antagonist multipledose protocols for poor-responder patients: a randomized study. Fertil Steril 2009; 2:481-485.
17. De Placido G, Mollo A, Alviggi C, Strina I, Varricchio MT, Ranieri A, Colacurci N, Tolino A, Wilding M. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum Reprod 2001;9:1875-1879.
18. De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, De Palo R, Ranieri A, Colacurci N, Mollo A et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled. Hum Reprod 2005;2:390-396.
19. DePlacido G, Mollo A, Clarizia R, Strina I, Conforti S, Alviggi C. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response. Fertil Steril 2006;1:247-250.
20. Devine K, Mumford SL, Wu M, DeCherney AH, Hill MJ, Propst A. Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System. Fertil Steril 2015;104:612-619.
21. Dias S, McNamee R, Vail A. Evidence of improving quality of reporting of randomized controlled trials in subfertility. Hum Reprod 2006;10:2617-2627.
22. Dimick JB, Diener-West M, Lipsett PA. Negative results of randomized clinical trials published in the surgical literature: equivalency or error? Arch Surg 2001;7:796-800.
23. Fabregues F, Penarrubia J,CreusM,ManauD,CasalsG,Carmona F,BalaschJ.Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Hum Reprod 2009;2:349-359.
24. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;7:1616-1624.
25. Ferraretti AP, Motrenko T, Feliciani E, Tabanelli C, Magli MC, Gianaroli L. LH pretreatment as a novel strategy for poor responders. BioMed Res Int 2014;ID926172.
26. Griesinger G, Venetis CA, Tarlatzis B, Kolibianakis EM. To pill or not to pill in GnRH-antagonist cycles: the answer is in the data already! Reprod Biomed Online 2015;1:6-8.
27. Hamdine O, Eijkemans MJ, Lentjes EG, Torrance HL, Macklon NS, Fauser BC, Broekmans FJ. Antimullerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization. Fertil Steril 2015;104:891-898.
28. Hemminki E, Hovi SL, Veerus P, Sevon T, Tuimala R, Rahu M, Hakama M. Blinding decreased recruitment in a prevention trial of postmenopausal hormone therapy. J Clin Epidemiol 2004;12:1237-1243.
29. Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Mullerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update 2014a;21:698-710.
30. Iliodromiti S, Kelsey TW, Wu O, Anderson RA, Nelson SM. The predictive accuracy of anti-Mullerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update 2014b; 4:560-570.
31. Johnson MO, Remien RH. Adherence to research protocols in a clinical context: challenges and recommendations from behavioral intervention trials. Am J Psychother 2003;3:348-360.
32. Kara M, Aydin T, Aran T, Turktekin N, Ozdemir B. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve? Eur J Obstet Gynecol Reprod Biol 2014;173:63-65.
33. Kahraman K, Berker B, Atabekoglu CS, Sonmezer M, Cetinkaya E, Aytac R, Satiroglu H. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. Fertil Steril 2009;6:2437-2444.
34. Kansal Kalra S, Ratcliffe S, GraciaCR, Martino L, Coutifaris C, BarnhartKT. Randomized controlled pilot trial of luteal phase recombinant FSH stimulation in poor responders. Reproductive Biomedicine Online 2008;6:745-750.
35. Kim C, Jeon G, Cheon Y, Jeon I, Kim S, Chae H, Kang B. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low-dose long protocol in low responders undergoing IVF/ intracytoplasmic sperm injection. Fertil Steril 2009;5:1758-1760.
36. Kim C, Howles CM, Lee H. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil Steril 2011; 2:679-683.
37. Klinkert ER, Broekmans FJM, Looman CWN, Habbema JDF, te Velde ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod 2005;3:611-615.
38. Kucuk T, Sozen E. Luteal start of exogenous FSH in poor responder women. J Assist Reprod Genet 2007;12:635-638.
39. KucukT, Goktolga U, Sozen E. Efficiency of follicle-stimulating hormone,commenced in the luteal phase, for overcoming a poor response in assisted reproduction. J Obstet Gynaecol Res 2008;4:574-577.
40. Kutlusoy F, Guler I, Erdem M, Erdem A, Bozkurt N, Biberoglu EH, Biberoglu KO. Luteal phase support with estrogen in addition to progesterone increases pregnancy rates in in vitro fertilization cycles with poor response to gonadotropins. Gynecol Endocrinol 2014;5:363-366.
41. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014; 1:124-140.
42. La Marca A, Sighinolfi G, Argento C, Grisendi V, Casarini L, Volpe A, Simoni M. Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization. Fertil Steril 2013;4:970-978.
43. La Marca A, Grisendi V, Giulini S, Sighinolfi G, Tirelli A, Argento C, Re C, Tagliasacchi D, Marsella T, Sunkara SK. Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study. J Assist Reprod Genet 2015; 6:931-937.
44. Lainas TG, Sfontouris IA, Papanikolaou EG, Zorzovilis JZ, Petsas GK, Lainas GT, Kolibianakis EM. Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial. Hum Reprod 2008;6:1355-1358.
45. Levens ED, WhitcombBW, Payson MD, Larsen FW. Ovarian follicular flushing among low-responding patients undergoing assisted reproductive technology. Fertil Steril 2009;4 Suppl:1381-1384.
46. Lindstrom H, Waldau S. Ethically acceptable prioritisation of childless couples and treatment rationing: 'accountability for reasonableness'. Eur J Obstet Gynecol Reprod Biol 2008;2:176-186.
47. Machin D, Day S, Green S (eds). Textbook of Clinical Trials.NewJersey, USA:Wiley, 2007.
48. Maggard MA, O'Connell JB, Liu JH, Etzioni DA, Ko CY. Sample size calculations in surgery: are they done correctly? Surgery 2003;2:275-279.
49. Malmusi S, La Marca A, Giulini S, Xella S, Tagliasacchi D, Marsella T, Volpe A. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation. Fertil Steril 2005:2;402-406.
50. Marci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M. GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reproductive Biomedicine Online 2005;2:189-193.
51. Marusic A, Ferencic SF. Adoption of the double dummy trial design to reduce observer bias in testing treatments. J R Soc Med 2013;5:196-198.
52. Massin N, Cedrin-Durnerin I, Coussieu C, Galey-Fontaine J,Wolf JP, Hugues J. Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique-a prospective, randomized, double-blind study. Hum Reprod 2006;5:1204-1211.
53. Martinez F,Coroleu B, Marques L, Parera N, Buxaderas R, Tur R, Barri PN. Comparison of "short protocol" versus "antagosnits" with or without clomiphene citrate for stimulation in IVF of patients with "low response". Revista Iberoamericana de Fertilidad y Reproduccion Humana 2003;6:355-360.
54. Minns Lowe CJ, Wilson MS, Sackley CM, Barker KL. Blind outcome assessment: the development and use of procedures to maintain and describe blinding in a pragmatic physiotherapy rehabilitation trial. Clin Rehabil 2011;3:264-274.
55. Moawad A, Shaeer M. Long-term androgen priming by use of dehydroepiandrosterone (DHEA) improves IVF outcome in poor-responder patients. A randomized controlled study. Middle East Fer Soc J 2012;17:268-274.
56. Moher D, Schulz KF, AltmanDG. TheCONSORTstatement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 9263:1191-1194.
57. Mok-Lin E, Brauer AA, Schattman G, Zaninovic N, Rosenwaks Z, Spandorfer S. Follicular flushing and in vitro fertilization outcomes in the poorest responders: a randomized controlled trial. Hum Reprod 2013;11:2990-2995.
58. Moore GF, Audrey S, Barker M, Bond L, Bonell C, HardemanW,Moore L, O'Cathain A, TinatiT,WightDet al. Process evaluation of complex interventions:MedicalResearch Council guidance. Br Med J 2015;350:h1258.
59. Morgia F, Sbracia M, Schimberni M, Giallonardo A, Piscitelli C, Giannini P, Aragona C.A controlled trial of natural cycle versus microdose gonadotropin-releasing hormone analog flare cycles in poor responders undergoing in vitro fertilization. Fertil Steril 2004;6:1542-1547.
60. Nargund G, Fauser BC, Macklon NS, Ombelet W, Nygren K, Frydman R; Rotterdam ISMAAR Consensus Group on Terminology for Ovarian Stimulation for IVF. The ISMAAR proposal on terminology for ovarian stimulation for IVF. Hum Reprod 2007;11:2801-2804.
61. Nelson SM,Pastuszek E,Kloss G,Malinowska I, Liss J,Lukaszuk A,Plociennik L,Lukaszuk K. Two new automated, compared with two enzyme-linked immunosorbent, antimullerian hormone assays. Fertil Steril 2015;104:1016-1021.
62. Nielsen ME, Rasmussen IA, Kristensen SG, Christensen ST, Mollgard K, Wreford Andersen E, Byskov AG, Yding Andersen C. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol Hum Reprod 2011;1:63-70.
63. Oudendijk JF, Yarde F, Eijkemans MJ, Broekmans FJ, Broer SL. The poor responder in IVF: is the prognosis always poor? A systematic review. Hum Reprod Update 2012; 1:1-11.
64. Page SJ, Persch AC. Recruitment, retention, and blinding in clinical trials. Am J Occup Ther 2013;2:154-161.
65. Page MJ, McKenzie JE, Kirkham J, Dwan K, Kramer S, Green S, Forbes A. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. Cochrane Database Syst Rev 2014; 1:MR000035.
66. Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev 2010;1:CD004379.
67. Papathanasiou A. Implementing the ESHRE 'poor responder' criteria in research studies: methodological implications. Hum Reprod 2014;9:1835-1838.
68. Patrizio P, Vaiarelli A, Levi Setti PE, Tobler KJ, Shoham G, Leong M, Shoham Z. How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics. Reprod Biomed Online 2015;6:581-592.
69. Polyzos NP, Sunkara SK. Sub-optimal responders following controlled ovarian stimulation: an overlooked group?Hum Reprod 2015 doi:10.1093/humrep/dev149.
70. Prapas Y, Petousis S, Dagklis T, Panagiotidis Y, Papatheodorou A, Assunta I, Prapas N. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2013;1:43-46.
71. Pu D, Wu J, Liu J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum Reprod 2011;10:2742-2749.
72. Ragni G, Levi-Setti P, Fadini R, Brigante C, Scarduelli C, Alagna F, Arfuso V, Mignini-Renzini M, Candiani M, Paffoni A et al. Clomiphene citrate versus high doses of gonadotropins for in vitro fertilisation in women with compromised ovarian reserve: a randomised controlled non-inferiority trial. Reprod Biol Endocrinol 2012; 10:114.
73. Revelli A, Chiado' A, Guidetti D, Bongioanni F, Rovei V, Gennarelli G. Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled study. J Assist Reprod Genet 2012;9:869-875.
74. Revelli A, Chiado A, Dalmasso P, Stabile V, Evangelista F, Basso G, Benedetto C. 'Mild' vs. 'long' protocol for controlled ovarian hyperstimulation in patients with expected poor ovarian responsiveness undergoing in vitro fertilization (IVF): a large prospective randomized trial. J Assist Reprod Genet 2014;7:809-815.
75. Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril 2007;3:542-546.
76. Schmidt DW, Bremner T, Orris JJ, Maier DB, Benadiva CA, Nulsen JC. A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. Fertil Steril 2005;5:1568-1571.
77. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J Am Med Assoc 1995;5:408-412.
78. Shahrokh Tehrani Nejad E, Hoseini Rashidi B, Ramezanzade F, Shariat M, Attar Shakeri B. GnRHa stop protocol versus long protocol in poor responder IVF patients. Iran J Reprod Med 2008;6:33-37.
79. Slovis BH, Check JH. Younger women with diminished oocyte reserve are not more prone to meiosis errors leading to spontaneous abortion than their age peers with normal oocyte reserve. Clin Exp Obstet Gynecol 2013;1:29-32.
80. Smulders B, van Oirschot SM, Farquhar C, Rombauts L, Kremer JA. Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database Syst Rev 2010;1:CD006109.
81. Steward RG, Lan L, Shah AA, Yeh JS, Price TM, Goldfarb JM, Muasher SJ. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 2014;4:967-973.
82. Sunkara SK, Coomarasamy A, Faris R, Braude P, Khalaf Y. Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. Fertil Steril 2014;1:147-153.
83. Sunkara SK, Tuthill J, Khairy M, El-Toukhy T, Coomarasamy A, Khalaf Y, Braude P. Pituitary suppression regimens in poor responders undergoing IVF treatment: a systematic review and meta-analysis. Reprod Biomed Online 2007;5:539-546.
84. Sunkara SK,Coomarasamy A, Arlt W,Bhattacharya S.Should androgensupplementation be used for poor ovarian response in IVF? Hum Reprod 2012;3:637-640.
85. Tanbo T, Abyholm T, Bjoro T, Dale PO. Ovarian stimulation in previous failures from in-vitro fertilization: distinction of two groups of poor responders.HumReprod 1990; 7:811-815.
86. Tazegul A, Gorkemli H, Ozdemir S, Aktan TM. Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. Arch Gynecol Obstet 2008;5:467-472.
87. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002;2:141-154.
88. Tierney JF, Stewart LA. Investigating patient exclusion bias in meta-analysis. Int J Epidemiol 2005;1:79-87.
89. Tur-Kaspa I, Fauser B. The use of GnRH agonist in IVF protocols. 2015. http://www.ivf-worldwide.com/survey/the-use-of-gnrh-agonist-in-ivf-protocols/results-the-useof-gnrh-agonist-in-ivf-protocols.html. (2 September 2015, date last accessed).
90. Veleva Z, Jarvela IY, Nuojua-Huttunen S, Martikainen H, Tapanainen JS. An initial low response predicts poor outcome in in vitro fertilization/intracytoplasmic sperm injection despite improved ovarian response in consecutive cycles. Fertil Steril 2005;5:1384-1390.
91. Weil SJ, Vendola K, Zhou J, Adesanya OO, Wang J, Okafor J, Bondy CA. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1998;7:2479-2485.
92. Weissman A, Farhi J, Royburt M, Nahum H, Glezerman M, Levran D. Prospective evaluation of two stimulation protocols for low responders who were undergoing in vitro fertilization-embryo transfer. Fertil Steril 2003;4:886-892.
93. Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 2010;10:2496-2500.
94. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. Br Med J 2008;7644:601-605.
95. Yeung TWY, Chai J, Li RHW, Lee VCY, Ho PC, Ng EHY. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertil Steril 2014;1:108-115.
96. Younis JS. The Bologna criteria for poor ovarian response; has the job been accomplished? Hum Reprod 2012;6:1874-1875.
97. Zlowodzki M, Bhandari M. Outcome measures and implications for sample-size calculations. J Bone Joint Surg Am 2009;91:35-40.